How to Avoid a Genetic Arms Race
By Yelena Biberman and Jonathan D. Moreno,
Bioethics Forum
| 04. 16. 2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the bad news. Great power conflicts and proxy wars are back. The rules-based world order crumbles while an unpredictable–and potentially unstable–multipolar one emerges.
Rapidly accelerating breakthroughs in our ability to change the genes of organisms are generating medically thrilling possibilities. They are also generating novel capabilities for biological weapons, a form of warfare that has been largely abandoned for decades. Take the recent AI-enabled advancements in gene-editing, construction of artificial viral vectors for human genome remodeling, protein folding, and the creation of custom proteins. Far outpacing the regulatory environment, these advances are facilitating the weaponization and delivery of harmful bioagents–overcoming impediments that previously made biological weapons impractical.
Speculation about “genetic weapons” capable of singling out specific groups for infection dates back to the 1970s. In 2012, Vladimir Putin mused publicly about weapons that could be “as effective as...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...